Samuel George A. III 4
4 · Lineage Cell Therapeutics, Inc. · Filed Feb 12, 2025
Insider Transaction Report
Form 4
Samuel George A. III
General Counsel and Secretary
Transactions
- Tax Payment
Common Shares
2025-02-11$0.65/sh−2,440$1,586→ 25,820 total - Exercise/Conversion
Common Shares
2025-02-11+6,076→ 28,260 total - Exercise/Conversion
Restricted Stock Units
2025-02-11−6,076→ 6,075 totalExercise: $0.00→ Common Shares (6,076 underlying)
Footnotes (4)
- [F1]Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis.
- [F2]Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options.
- [F3]Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction
- [F4]The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026.